AccessibilityHelpAbout Us

Korsana Biosciences(NASDAQ) KRSA

Market Cap$16.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-95%
1 Year+49%
1 Month-2%
$30.79
+25.35%
+6.22Today
Korsana Biosciences last closing stock price
MetricPriceDate
Last closeUSD 24.562026-09-10
Korsana Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-29.26%USD 34.722026-09-03
1 month-1.72%USD 24.992026-08-11
3 month+7.96%USD 22.752026-06-12
Year to date+176.27%USD 8.892025-12-31
1 year+48.5%USD 16.542025-09-10
3 year-11.73%USD 27.832023-09-11
5 year-94.64%USD 457.802021-09-10
Since inception-98.6%USD 1,750.002019-03-18

Korsana Biosciences Financials at a Glance

Market Cap

$16.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.90M

Net Income (TTM)

-$6.71M

EPS (TTM)

-$11.76

P/E Ratio

-2.09

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$30.79

Volume

35,194.326

Open

$25.22

Previous Close

$24.56

Daily Range

$25.22 - $32.03

52-Week Range

$7.19 - $59.36

Estimated Earnings Date

Nov 11, 2026

KRSA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Korsana Biosciences

Korsana Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative human therapeutics. The company specializes in sGC stimulators, which enhance nitric oxide signaling to improve cyclic guanosine monophosphate production.

Products and Services
  • Development of sGC stimulators for various therapeutic applications
  • Research focused on enhancing nitric oxide signaling
  • Pipeline includes multiple small molecule candidates
Growth Outlook
  • Market potential for sGC stimulators is expanding rapidly
  • Strong focus on research and development to drive innovation
  • Partnerships with leading research institutions enhance capabilities
Financial Highlights
  • Recent quarterly net income of -$1.76 million, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $1.03 million, indicating growth potential
  • Cash and cash equivalents of $1.39 million as of June 30, 2026
Korsana Biosciences, Inc. operates in the dynamic medical and pharmaceutical industry, with a focus on developing groundbreaking therapies. The company's innovative approach to enhancing nitric oxide signaling positions it well within a growing market. Recent financial data indicates a commitment to research and development, which is essential for long-term growth. The company’s cash reserves provide a foundation for continued investment in its product pipeline, while strategic partnerships may further enhance its research capabilities. Overall, Korsana Biosciences represents an intriguing opportunity for investors interested in the biopharmaceutical sector.
AI Generated • Sep 10, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Jonathan Violin, PhD, MBA

Website

www.cyclerion.com

Headquarters

Cambridge, MA 02420, US

KRSA Financials

Key Financial Metrics (TTM)

Gross Margin

61.58%

Operating Margin

-359.16%

Net Income Margin

-353.00%

Return on Equity

-87.96%

Return on Capital

-54.74%

Return on Assets

-96.78%

Earnings Yield

-47.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

668.80K

Volume

35.19K

Avg. Volume

7.45K

Financials (TTM)

Gross Profit

$1.17M

Operating Income

-$6.82M

EBITDA

-$6.71M

Operating Cash Flow

-$4.45M

Capital Expenditure

$0.00

Free Cash Flow

-$4.45M

Cash & ST Invst.

$1.39M

Total Debt

$0.00

Korsana Biosciences Performance Analysis

Korsana Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 297,000-92.5%
20232023-12-31USD 0N/A
20242024-12-31USD 2,000,000N/A
20252025-12-31USD 2,074,0003.7%
Korsana Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30840.9%
Q42025-12-3117.1%
Q12026-03-31-100.0%
Q22026-06-30N/A
Korsana Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -141.99-23.1%
20232023-12-31USD -62.92-55.7%
20242024-12-31USD -8.50-86.5%
20252025-12-31USD -7.76-8.6%
Korsana Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-172.7%
Q42025-12-3116.7%
Q12026-03-31-204.0%
Q22026-06-3046.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$16.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.42M

N/A

Employees

1

N/A

Net Income

-$1.76M

-441.7%

EBITDA

-$1.76M

-441.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.39M

-53.7%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-96.78%

N/A

Return on Invested Capital

-1.34%

N/A

Free Cash Flow

-$1.37M

-171.6%

Operating Cash Flow

-$1.43M

-184.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KTTAPasithea Therapeutics Corp.
$0.53-2.17%
VYNEVYNE Therapeutics Inc.
$28.56+0.00%
QNRXQuoin Pharmaceuticals, Ltd.
$6.79-1.59%
PLRZPolyrizon Ltd.
$10.93-2.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
ACVAACV Auctions
$10.44+0.45%
TNONTenon Medical
$8.93+0.68%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.46+0.05%
SMRNuScale Power
$8.78-0.14%

Questions About KRSA

What is the current price of Korsana Biosciences?

Korsana Biosciences is trading at $31.00 per share.

What is the 52-week range for Korsana Biosciences?

Over the past 52 weeks, Korsana Biosciences has traded between $7.19 and $59.36.

How much debt does Korsana Biosciences have?

As of the most recent reporting period, Korsana Biosciences reported total debt of $0.00.

How much cash does Korsana Biosciences have on hand?

Korsana Biosciences reported $1.39M in cash and cash equivalents in its most recent financial results.

What is Korsana Biosciences’s dividend yield?

Korsana Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services